Drug intelligence / Profile preview

imigliptin

Development stage: Preclinical
Lead developer: Xuanzhu Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Imigliptin is a novel small molecule dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Sihuan Group and Xuanzhu Pharma. It is being investigated for the treatment of type 2 diabetes mellitus, where it aims to improve insulin resistance and beta-cell function by inhibiting the DPP-4 enzyme. Preclinical studies have demonstrated its potent and selective DPP-4 inhibition with good tolerance.

Other names: Imigliptin Dihydrochloride

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on imigliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on imigliptin.

Explore the full profile